How India Exports Bisoprolol to the World

In the United States, bisoprolol is approved under the brand name Zebeta, with the original New Drug Application (NDA 19-982) approved on July 31, 1992. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for bisoprolol, indicating a competitive generic market. As of March 2026, there are no active FDA import alerts specifically targeting bisoprolol products from India, suggesting compliance with U.S. regulatory standards. The substantial number of Indian exporters (245) underscores the robust participation of Indian manufacturers in the U.S. bisoprolol market.

In the European Union, bisoprolol is subject to marketing authorization by the European Medicines Agency (EMA). On February 15, 2023, the EMA recommended the authorization of Rambis, a combination of ramipril and bisoprolol, indicating ongoing regulatory evaluations and approvals for bisoprolol-containing products. The United Kingdom, through the Medicines and Healthcare products Regulatory Agency (MHRA), aligns with EMA standards, requiring compliance with EU Good Manufacturing Practice (GMP) guidelines for bisoprolol products.

Bisoprolol is included in the World Health Organization's (WHO) Model List of Essential Medicines, reflecting its importance in global health. While specific editions of the list should be consulted for confirmation, its inclusion underscores the drug's recognized efficacy and safety. Bisoprolol formulations are standardized across major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring consistent quality and therapeutic equivalence worldwide.

In India, bisoprolol is classified under Schedule H of the Drugs and Cosmetics Act, indicating it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, as of March 2026, bisoprolol is not listed under the Drug Price Control Order (DPCO), allowing market-driven pricing. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) for pharmaceutical products, ensuring compliance with international standards and regulations.

The primary patents for bisoprolol have expired, facilitating the entry of generic versions into the market. This has led to increased competition among manufacturers, including Indian exporters, contributing to the drug's widespread availability and affordability globally.

In December 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended the authorization of Rambis, a combination of ramipril and bisoprolol, highlighting ongoing developments in combination therapies involving bisoprolol. In October 2025, the EMA issued a variation to the marketing authorization for bisoprolol/hydrochlorothiazide products, emphasizing the need for updated product information regarding the risk of hypoglycemia when used concomitantly with sulfonylureas. These regulatory actions reflect the dynamic nature of bisoprolol's market and the importance of continuous monitoring and compliance with evolving standards.

India's pharmaceutical industry heavily relies on China for Key Starting Materials (KSMs) essential in Active Pharmaceutical Ingredient (API) production. Approximately 70% of India's API imports originate from China, underscoring a significant dependency. This reliance exposes the supply chain to potential disruptions stemming from geopolitical tensions, trade restrictions, or production halts in China. For instance, environmental regulations in China have previously led to the shutdown of chemical manufacturing units, causing supply shortages and price volatility for Indian pharmaceutical companies.

To mitigate this dependency, the Indian government launched the Production Linked Incentive (PLI) scheme for bulk drugs in 2020, aiming to bolster domestic production of critical APIs and KSMs. By August 2025, the scheme had approved 48 projects across 33 APIs/KSMs, resulting in cumulative sales of INR 19.62 billion (approximately $218.3 million USD) and import substitution worth INR 14.83 billion (around $165 million USD). Despite these efforts, the transition to self-reliance is gradual, and the industry remains vulnerable to external supply chain disruptions.

The bisoprolol export market from India is notably concentrated among a few suppliers. The top five exporters—Unichem Laboratories Limited, Fredun Pharmaceuticals Ltd, IPCA Laboratories Limited, Aurobindo Pharma Ltd, and Medreich Limited—collectively account for 74.9% of the total export value. Unichem Laboratories Limited alone contributes 34.2% of the exports, indicating a high level of supplier concentration. Such dependency on a limited number of suppliers increases the risk of supply chain disruptions due to operational issues, regulatory challenges, or financial instability within these companies.

The PLI scheme aims to diversify and strengthen the supplier base by encouraging new entrants and expanding existing capacities. As of September 2025, the scheme had attracted investments exceeding initial commitments, with actual investments reaching INR 408.90 billion (approximately $4.54 billion USD). While these initiatives are promising, their impact on reducing supplier concentration in the bisoprolol market is yet to be fully realized.

Global shipping routes, including the Red Sea and the Strait of Hormuz, are critical for the transportation of pharmaceutical products. Any geopolitical tensions or conflicts in these regions can lead to shipping delays, increased costs, and supply chain disruptions. Additionally, escalating tensions between major economies, such as the United States and China, can result in trade restrictions or tariffs that may indirectly affect the pharmaceutical supply chain.

Regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have occasionally issued shortage alerts for various drugs due to supply chain issues. While specific alerts for bisoprolol have not been prominent, the interconnected nature of the pharmaceutical supply chain means that disruptions in one area can have cascading effects on others.

• Diversify API and KSM Sources: Encourage the development of alternative suppliers for APIs and KSMs, both domestically and in other countries, to reduce dependency on a single source.

• Strengthen Domestic Manufacturing: Accelerate the implementation of the PLI scheme and similar initiatives to enhance domestic production capabilities for critical pharmaceutical ingredients.

• Enhance Supplier Due Diligence: Conduct regular assessments of key suppliers' financial health, regulatory compliance, and operational stability to identify potential risks early.

• Develop Contingency Plans: Establish robust contingency plans, including maintaining strategic stockpiles and identifying alternative logistics routes, to mitigate the impact of geopolitical and shipping disruptions.

• Monitor Regulatory Developments: Stay informed about international regulatory changes and potential trade restrictions that could affect the pharmaceutical supply chain, and adapt strategies accordingly.

RISK_LEVEL: MEDIUM